A recent narrative review looks at the most effective and emerging options for diagnosing and treating basal cell carcinoma.
Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.
Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain ...
A new study led by researchers at the Institute of Materials Science of Barcelona (ICMAB-CSIC) reveals why a particular boron ...
Sofetabart mipitecan (LY4170156), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), elicited strong antitumor activity in patients with recurrent ...
Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for ...
A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...
Head and neck cancers represent a biologically heterogeneous group of malignancies requiring accurate diagnosis, staging, and risk stratification for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results